{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:07:50Z","timestamp":1764331670256},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Orthop\u00e4de"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1007\/s00132-006-1035-6","type":"journal-article","created":{"date-parts":[[2007,1,24]],"date-time":"2007-01-24T07:55:00Z","timestamp":1169625300000},"page":"110-117","source":"Crossref","is-referenced-by-count":2,"title":["Bisphosphonate in der Osteoporosetherapie"],"prefix":"10.1007","volume":"36","author":[{"given":"S.","family":"Reinsdorf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Hochmuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.A.","family":"Kurth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1035_CR1","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMc062268","volume":"355","author":"Armamento-Villareal","year":"2006","unstructured":"Armamento-Villareal R, Napoli N, Panwar V, Novack D (2006) Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 355: 2048\u20132050","journal-title":"N Engl J Med"},{"key":"1035_CR2","first-page":"45","volume":"19","author":"Black","year":"2004","unstructured":"Black D, Schwartz A, Ensrud K et al. (2004) A 5\u00a0year randomized trial of the long-term efficary and safety of alendronate: The FIT Long-term Extension (FLEX). J Bone Miner Metab 19(Suppl 1): 45","journal-title":"J Bone Miner Metab"},{"key":"1035_CR3","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","volume":"85","author":"Black","year":"2000","unstructured":"Black DM, Thompson DE, Bauer DC et al. (2000) Fracture risk reduction with alendronate in women with osteoporosis: theFracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85: 4118\u20134124","journal-title":"J Clin Endocrinol Metab"},{"key":"1035_CR4","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","volume":"350","author":"Bone","year":"2004","unstructured":"Bone HG, Hosking D, Devogelaer JP et al. (2004) Ten years\u2018 experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189\u20131199","journal-title":"N Engl J Med"},{"key":"1035_CR5","first-page":"346","volume":"2006","author":"Boonen","year":"2006","unstructured":"Boonen S, Orwoll ES, Wenderoth D et al. (2006) Risedronate is effective in men with osteoporosis regardless of baseline testosterone level and prevalent vertebral fracture status. ASMBR 2006: 346","journal-title":"ASMBR"},{"key":"1035_CR6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1359\/jbmr.2001.16.1.104","volume":"16","author":"Boutsen","year":"2001","unstructured":"Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP (2001) Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion and infusion given once every 3 months, and calcium alone. J Bone Miner Res 16: 104\u2013112","journal-title":"J Bone Miner Res"},{"key":"1035_CR7","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"Chestnut","year":"2004","unstructured":"Chestnut III CH, Skag A, Christiansen C et al. (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19: 1241\u20131249","journal-title":"J Bone Miner Res"},{"key":"1035_CR8","first-page":"21391","volume":"2005","author":"Chesnut","year":"2005","unstructured":"Chesnut III CH, Ettinger MP, Miller PD et al. (2005) Ibandronate producessignificant, similar antifractureefficacy in North American and European women: new clinicalfindings from bone. Curr Med Res Opin 2005: 21391\u20132401","journal-title":"Curr Med Res Opin"},{"key":"1035_CR9","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","volume":"42","author":"Cohen","year":"1999","unstructured":"Cohen S, Levy RM, Keller M et al. (1999) Risedronates therapy prevents corticosteroid-induced osteoporosis bone loss. Arthritis Rheum 42: 2309\u20132318","journal-title":"Arthritis Rheum"},{"key":"1035_CR10","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s001980170147","volume":"12","author":"Cranney","year":"2001","unstructured":"Cranney A, Guyatt G, Krolickin et al. (2001) A metaanalysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporosis Research Advisory Group. Osteoporos Int 12: 140\u2013151","journal-title":"Osteoporos Int"},{"key":"1035_CR11","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","volume":"54","author":"Delmas","year":"2006","unstructured":"Delmas PD, Adami S, Strugala C et al. (2006) Intravenous Ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study. Art Rheum 54: 1838\u20131846","journal-title":"Art Rheum"},{"key":"1035_CR12","first-page":"163","volume":"16","author":"Eastell","year":"2001","unstructured":"Eastell R, Barton I, Hannon R et al. (2001) Antifracture efficacy of risedronate prediction by change in bone resorption markers. J Bone Miner Res 16: 163","journal-title":"J Bone Miner Res"},{"key":"1035_CR13","first-page":"3078","volume":"103","author":"Felsenberg","year":"2006","unstructured":"Felsenberg D, Hoffmeister B, Amling M et al. (2006) Kiefernekrosen nach hoch dosierterBisphosphonattherapie. Dtsch Arztebl A 103: 3078\u20133080","journal-title":"Dtsch Arztebl A"},{"key":"1035_CR14","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.bone.2005.05.004","volume":"37","author":"Felsenberg","year":"2005","unstructured":"Felsenberg D, Miller PD, Armbrecht G et al. (2005) Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone 37: 651\u2013654","journal-title":"Bone"},{"key":"1035_CR15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","volume":"19","author":"Fleisch","year":"1998","unstructured":"Fleisch H (1998) Bisphosphonates: mechanisms of action. Endo Rev 19: 80\u2013100","journal-title":"Endo Rev"},{"key":"1035_CR16","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282: 1344\u20131352","journal-title":"JAMA"},{"key":"1035_CR17","first-page":"315","volume":"60","author":"Heijckmann","year":"2002","unstructured":"Heijckmann AC, Juttman JR, Wolffenbuttel BH (2002) Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis. Neth J Med 60: 315\u2013319","journal-title":"Neth J Med"},{"key":"1035_CR18","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S8756-3282(01)00414-8","volume":"28","author":"Mashiba","year":"2001","unstructured":"Mashiba T, Turner CH, Hirano T et al. (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28: 524\u2013531","journal-title":"Bone"},{"key":"1035_CR19","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S8756-3282(00)00437-3","volume":"28","author":"McCloskey","year":"2001","unstructured":"McCloskey E, Selby P, deTakats D et al. (2001) Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis. Bone 28: 310\u2013315","journal-title":"Bone"},{"key":"1035_CR20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"McClung","year":"2001","unstructured":"McClung M, Geusens P, Miller P et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344: 333\u2013340","journal-title":"N Engl J Med"},{"key":"1035_CR21","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","volume":"75","author":"Mellstrom","year":"2004","unstructured":"Mellstrom DD, Sorensen OH, Goemaere S et al. (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75: 462\u2013468","journal-title":"Calcif Tissue Int"},{"key":"1035_CR22","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0002-9343(97)00278-7","volume":"103","author":"Miller","year":"1997","unstructured":"Miller PD, Watts NB, Licata AA et al. (1997) Cyclic etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am J Med 103: 468\u2013476","journal-title":"Am J Med"},{"key":"1035_CR23","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","volume":"20","author":"Miller","year":"2005","unstructured":"Miller PD, McClung MR, Macovei L et al. (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20: 1315\u20131322","journal-title":"J Bone Miner Res"},{"key":"1035_CR24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","volume":"343","author":"Orwoll","year":"2000","unstructured":"Orwoll E, Ettinger M, Weiss S et al. (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343: 604\u2013610","journal-title":"N Engl J Med"},{"key":"1035_CR25","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","volume":"9","author":"Pols","year":"1999","unstructured":"Pols HA, Felsenberg D, Hanley DA et al. (1999) Multinational, placebo-controlled, randomized trial of the effects ofalendronate on bone density and fracture risk in postmenopausal women with lowbone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9: 461\u2013468","journal-title":"Osteoporos Int"},{"key":"1035_CR26","first-page":"45","volume":"19","author":"Recker","year":"2004","unstructured":"Recker R, Ensrud K, Diem S et al. (2004) Normal Bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women. J Bone Miner Metab 19(Suppl 1): 45","journal-title":"J Bone Miner Metab"},{"key":"1035_CR27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with estabilished postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11: 83\u201391","journal-title":"Osteoporos Int"},{"key":"1035_CR28","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/S0140-6736(89)92927-9","volume":"2","author":"Reginster","year":"1989","unstructured":"Reginster JY, Lecart MP, Deroisy R, et al. (1989) Prevention of postmenopausal bone loss by tiludronate. Lancet 2: 1469\u20131471","journal-title":"Lancet"},{"key":"1035_CR29","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","volume":"65","author":"ReginsterJY","year":"2006","unstructured":"ReginsterJY, Adami S, Lakatos P et al. (2006) Efficacy and tolerability of once-monthly oralibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 65: 654\u2013661","journal-title":"Ann Rheum Dis"},{"key":"1035_CR30","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","volume":"15","author":"Reid","year":"2000","unstructured":"Reid DM, Hughes RA, Laan RF et al. (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-indurced osteoporosis in men and women: a randomized trial. J Bone Miner Res 15: 1006\u20131123","journal-title":"J Bone Miner Res"},{"key":"1035_CR31","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00198-003-1425-0","volume":"14","author":"Ringe","year":"2003","unstructured":"Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F (2003) Intermittent intravenous ibandronate injections reduce vertebral fracture risk in cortcosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 14: 801\u2013807","journal-title":"Osteoporos Int"},{"key":"1035_CR32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S8756-3282(99)00116-7","volume":"25","author":"Rogers","year":"1999","unstructured":"Rogers MJ, Russell RGG (1999) Bisphosphonates: from the labortory to the clinic and back again. Bone 25: 97\u2013106","journal-title":"Bone"},{"key":"1035_CR33","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1185\/030079903125003125","volume":"20","author":"Roux","year":"2004","unstructured":"Roux C, Seeman E, Eastell R et al. (2004) Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20: 433\u2013439","journal-title":"Curr Med Res Opin"},{"key":"1035_CR34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","volume":"339","author":"Saag","year":"1998","unstructured":"Saag KG, Emkey R, Schnitzer TJ et al. (1998) Alendronate fort he prevention and treatment of glucocorticoid-induced osteoporosis. N Eng J Med 339: 292\u2013299","journal-title":"N Eng J Med"},{"key":"1035_CR35","first-page":"The","volume":"therapy","author":"Silverman","year":"2006","unstructured":"Silverman SL, Watts NB, Delmas PD et al. (2006) Effectiveness of bisphosphonates on nonvertebral and hipfractures in the first year of therapy: The risedronateand alendronate (REAL) cohort study. Osteoporos Int DOI 10.1007\/s00198\u2013006\u20130274","journal-title":"Effectiveness of bisphosphonates on nonvertebral and hipfractures in the first year of"},{"key":"1035_CR36","first-page":"1560","volume":"23","author":"Storm","year":"1996","unstructured":"Storm T, Kollerup G, Thamsborg G et al. (1996) Five years of clinical experience with intermittent cyclic etidronate for postmenopausal osteoporosis. J Rheumatol 23: 1560\u20131564","journal-title":"J Rheumatol"},{"key":"1035_CR37","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0002-9343(97)00249-0","volume":"103","author":"Thiebaud","year":"1997","unstructured":"Thiebaud D, Burckhardt P, Kriegbaum H et al. (1997) Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103: 298\u2013307","journal-title":"Am J Med"},{"key":"1035_CR38","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S8756-3282(01)00655-X","volume":"30","author":"Van","year":"2002","unstructured":"Van Beek ER, Lowik CW. Papapoulos SE (2002) Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 30: 64\u201370","journal-title":"Bone"},{"key":"1035_CR39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/rheumatology\/37.1.87","volume":"37","author":"van","year":"1998","unstructured":"van Staa TP, Abenhaim L, Cooper C (1998) Use of cyclic etidronate and prevention of nonvertebral fractures. Br J Rheumatol 37: 87\u201394","journal-title":"Br J Rheumatol"},{"key":"1035_CR40","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1258\/0004563011901037","volume":"38","author":"Vasikaran","year":"2001","unstructured":"Vasikaran SD (2001) Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem 38: 608\u2013623","journal-title":"Ann Clin Biochem"},{"key":"1035_CR41","first-page":"311","volume":"19","author":"Vis","year":"2004","unstructured":"Vis M, Bultink L, Dijkmans B, Lems W (2004) The effect of oral alendronate versus intravenous pamindronate on bone mineral density in patients with osteoporosis. J Bone Miner Metab 19(Suppl 1): 311","journal-title":"J Bone Miner Metab"},{"key":"1035_CR42","first-page":"407","volume":"16","author":"Watts","year":"2001","unstructured":"Watts N, Adami S, Chesnut CH 3rd et al. (2001) Risedronate reduces the risk of clinical vertebral fractures in just 6 months. J Bone Miner Res 16: 407","journal-title":"J Bone Miner Res"},{"key":"1035_CR43","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0889-857X(05)70194-0","volume":"27","author":"Watts","year":"2001","unstructured":"Watts NB (2001) Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am 27: 197\u2013214","journal-title":"Rheum Dis Clin North Am"},{"key":"1035_CR44","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","volume":"349","author":"Whyte","year":"2003","unstructured":"Whyte MP, Wenkert D, Clements KL et al. (2003) Bisphosphonate-induced osteopetrosis. N Engl J Med 349: 457\u2013463","journal-title":"N Engl J Med"},{"key":"1035_CR45","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0002-9343(98)00029-1","volume":"104","author":"Wimalawansa","year":"1998","unstructured":"Wimalawansa SJ (1998) A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 104: 219\u2013226","journal-title":"Am J Med"}],"container-title":["Der Orthop\u00e4de"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00132-006-1035-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00132-006-1035-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00132-006-1035-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T08:37:21Z","timestamp":1558600641000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00132-006-1035-6"}},"subtitle":["Standards und Perspektiven"],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["1035"],"URL":"https:\/\/doi.org\/10.1007\/s00132-006-1035-6","relation":{},"ISSN":["0085-4530","1433-0431"],"issn-type":[{"value":"0085-4530","type":"print"},{"value":"1433-0431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}